Medicare clarifies coverage for rare-disease treatment in nursing homes
H.R. 8528 — PI Post Acute Access Act · Filed by Adrian Smith (R-NE) · 7 cosponsors · Introduced Apr 27, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends Medicare's skilled nursing facility (SNF) payment rules to explicitly cover intravenous immune globulin (IVIG) treatments and related services for patients with primary immunodeficiency disease, effective October 1, 2026. Currently, Medicare SNF coverage for IVIG is ambiguous or denied; this bill clarifies that IVIG and the nursing/infusion services needed to deliver it are covered benefits, allowing immunodeficiency patients to receive this critical treatment in SNFs rather than only in hospitals or outpatient clinics.
Why we flagged it
The bill is a straightforward technical amendment to Medicare's SNF benefit rules, adding a specific drug and related services to the covered-items list. It is not a new program, subsidy, or deregulation—it is a clarification of existing benefit scope.
What the text implies
- IVIG manufacturers (Grifols, CSL Behring, Takeda, Octapharma) may see increased volume and revenue if SNF-based IVIG delivery expands, though the bill does not mandate IVIG use—it only clarifies coverage.
- SNFs may need to invest in infusion infrastructure and staff training to deliver IVIG safely, creating upfront costs offset by Medicare reimbursement.
- The effective date (October 1, 2026) aligns with the Medicare fiscal year, suggesting coordination with CMS payment-rule cycles.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Patients with primary immunodeficiency disease gain explicit Medicare coverage for a medically necessary treatment (IVIG) in a lower-cost post-acute setting, reducing treatment delays, improving access, and lowering out-of-pocket costs. SNF-based IVIG delivery is less expensive than hospital-based delivery and allows patients to recover closer to home.
Who stands to gain
- intravenous immunoglobulin manufacturers
- skilled nursing facilities
- patients with primary immunodeficiency disease (reduced out-of-pocket costs)
Named in the bill
Centers for Medicare & Medicaid Services (CMS), Social Security Act Section 1888, HCPCS codes J1561, J1569, J1576, J1568, J1459, J1554, J1557, J1566, primary immunodeficiency disease, intravenous immune globulin (IVIG), skilled nursing facilities (SNFs)
Where it stands
7 cosponsors: 5 Democrats, 2 Republicans.
- Apr 27, 2026 — Introduced · Congress.gov: “Introduced in House”
- Apr 27, 2026 — Referred to House Committee on Energy and Commerce and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (742 characters) on Aug 24, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Medicare clarifies coverage for rare-disease treatment in nursing homes” QuorumCivic. https://share.quorumcivic.app/bill/119/hr8528 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.